CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Maravirocdrug
Likely dose
Maraviroc 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01276236
NCT01276236Phase 2Completed
CompareCT.gov

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

University of California, San Francisco·interventional·Posted Jan 13, 2011·Updated Mar 5, 2021

In Brief

A Phase 2 clinical trial evaluating Maraviroc for Kaposi's Sarcoma. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The purpose of this pilot study is to determine whether Maraviroc is effective in the treatment of Kaposi's Sarcoma (KS), when it does not remit with standard antiretroviral drug therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKaposi's Sarcoma
CountriesUnited States
CollaboratorsPfizer, ViiV Healthcare

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 13, 2011
Enrollment StartMar 9, 2011
Primary CompletionJan 31, 2015
Study CompletionApr 30, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 15.5 years ago

Interventions

Maravirocdrug

FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks. Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks. Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions.